Cargando…

Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner

The molecular mechanism of the tyrosine kinase inhibitor (TKI) resistant lung adenocarcinoma is currently unclear, and the role of methylated adenosine at the N6 position in the resistance of cancer stem cells (CSCs) therapy is unknown. This study identified a novel and effective strategy to enhance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kai, Gao, Shan, Ma, Lei, Sun, Ye, Peng, Zi-Yang, Wu, Jie, Du, Ning, Ren, Hong, Tang, Shou-Ching, Sun, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770959/ https://www.ncbi.nlm.nih.gov/pubmed/35070958 http://dx.doi.org/10.3389/fonc.2021.731561

Ejemplares similares

The insights of Let‐7 miRNAs in oncogenesis and stem cell potency
por: Sun, Xin, et al.
Publicado: (2016)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

Dual mechanism of Let-7i in tumor progression
por: Zhou, Jiapei, et al.
Publicado: (2023)

Let-7 underlies metformin-induced inhibition of hepatic glucose production
por: Xie, Di, et al.
Publicado: (2022)

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer
por: Cui, Nai-Peng, et al.
Publicado: (2021)

Tyrosine kinases in nodal peripheral T-cell lymphomas
por: Piccaluga, Pier Paolo, et al.
Publicado: (2023)

MiR-21 and let-7 cooperation in the regulation of lung cancer
por: Bai, Jinquan, et al.
Publicado: (2022)

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro
por: Yang, Yuqi, et al.
Publicado: (2020)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
por: Takahashi, Aya, et al.
Publicado: (2021)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
por: Tian, Zhichao, et al.
Publicado: (2020)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

The Neurogenic Compound P7C3 Regulates the Aerobic Glycolysis by Targeting Phosphoglycerate Kinase 1 in Glioma
por: Chen, Wenjin, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
por: Zhao, Yuming, et al.
Publicado: (2021)

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner
por: Rattan, R, et al.
Publicado: (2011)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma
por: Shi, Guizhi, et al.
Publicado: (2009)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
por: Ma, Jianhui, et al.
Publicado: (2020)

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
por: Shi, Binhao, et al.
Publicado: (2023)

A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors
por: Han, Ji Min, et al.
Publicado: (2022)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
por: He, Fang, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
por: Zhang, Ninggang, et al.
Publicado: (2022)

Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
por: He, Fang, et al.
Publicado: (2021)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021)

Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface
por: Rapraeger, Alan C.
Publicado: (2021)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
por: Wang, Liang, et al.
Publicado: (2021)

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
por: Abbas, Hussein A., et al.
Publicado: (2021)

Breast cancer stem-like cells are sensitized to tamoxifen induction of self-renewal inhibition with enforced Let-7c dependent on Wnt blocking
por: Sun, Xin, et al.
Publicado: (2018)

Nano Let-7b sensitization of eliminating esophageal cancer stem-like cells is dependent on blockade of Wnt activation of symmetric division
por: Pang, Yamei, et al.
Publicado: (2017)

Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer
por: Peng, Zi-Yang, et al.
Publicado: (2022)

DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1
por: Sun, Xin, et al.
Publicado: (2015)

A vesicle surface tyrosine kinase regulates phagosome maturation
por: Fang, Jun, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_3bqn47bt640lv0ksapqr0ua7ro